Biotech Values

[poorgradstudent]

ONXX:

I'm interested in knowing what the enrolled patient population looks like. The inclusion criteria on clinicaltrials.gov seem quite broad, so I'm curious to know just how "heavily pre-treated" the patients were. The inclusion criteria seem to allow for patients who have failed only one standard regimen, and so if second line patients were able to enroll in the study, I don't think showing a benefit against placebo is particularly impressive.

I'm very weak on the treatment strategies for CRC.

However, isn't best supportive care usually reserved for patients with no other approved treatment options? That would place this trial in a last-ditch population. That would also be consistent with the description provided at your link: patients with metastatic colorectal cancer (CRC) who have progressed on/after all approved drugs for CRC.